Mineralys Therapeutics Inc（MLYS）價格預測MLYSMineralys Therapeutics Inc

Alphio's MLYS stock price prediction model matches the current Mineralys Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $20.84 (+1.38%). The 1-week path is $21.13 (+2.76%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Currently, Mineralys Therapeutics Inc (MLYS) is not a strong buy due to its significant recent losses and negative technical indicators. The stock is trading at $20.55, which is down 42.45% year-to-date and 49.33% over the past year. The RSI is at 36.371, indicating it is nearing oversold territory, but the MACD shows a bearish trend with a value of -1.431. The company has posted substantial losses, with a net income of -241 million in Q2 2026, and a forward P/E ratio of 0 suggests uncertainty in future earnings. The main risk is the company's declining equity, which dropped to $550 million in Q2 2026 from $646 million in Q4 2025. Given these factors, it may be prudent to hold off on buying until there are clearer signs of recovery and improved financial performance.

Mineralys Therapeutics Inc (MLYS) last closed at $20.5599995, gaining +0.05%. These facts feed the 1-day and 1-week MLYS price prediction above.